Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Atezolizumab Combo Improves PFS by 3.5 Months in mRCC

February 6th 2018

The combination of atezolizumab and bevacizumab reduced the risk of progression or death by 26% compared with sunitinib for patients with untreated PD-L1–positive metastatic renal cell carcinoma.

Balar Addresses Advances in Bladder and Kidney Cancer

February 5th 2018

Arjun V. Balar, MD, discusses the landscape of current and future standards of care for immunotherapy in bladder and kidney cancer.

Can Immunotherapy Bypass Sequential Care in RCC?

February 2nd 2018

Despite positive clinical trial results, the role of immunotherapy in renal cell carcinoma remains unclear.

Cabozantinib QoL Similar to Everolimus in RCC Patients

February 2nd 2018

Patients with advanced renal cell carcinoma treated with cabozantinib had similar quality of life outcomes as those treated with everolimus.

Dr. Balar on Current and Future Standards of Care in Kidney Cancer Treatment

January 30th 2018

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses the potential of existing targeted therapy coupled with immunotherapy to improve overall survival (OS) in patients with kidney cancer.

Dr. Huang Discusses Robotic Surgery for Bladder Cancer

January 27th 2018

William C. Huang, MD, associate professor, department of Urology, co-director, Robotics Program, Chief Urology Service, Tisch Hospital, NYU Langone Health, discusses robotic surgery in the treatment of bladder cancer.

Dr. Zhang Discusses Neoadjuvant Therapy in Kidney Cancer

January 25th 2018

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses neoadjuvant therapy in kidney cancer.

Dr. McKay Discusses Combinations in Renal Cell Carcinoma

January 24th 2018

Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses combinations in renal cell carcinoma.

Cabozantinib Improves Survival in RCC Patients With Bone Metastases

January 23rd 2018

Cabozantinib (Cabometyx) was associated with an improvement in overall survival and progression-free survival compared with everolimus (Afinitor) in pretreated patients with advanced RCC with bone metastases at baseline.

Dr. McDermott on Novel Immunotherapy Combinations in RCC

January 20th 2018

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses novel immunotherapy combinations for patients with metastatic renal cell carcinoma (RCC).

Dr. Apolo on Managing Toxicities of Checkpoint Inhibitors in Bladder Cancer

January 19th 2018

Andrea B. Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses managing immune-related toxicities from checkpoint inhibitors in patients with bladder cancer.

Published Data Demonstrate Avelumab Activity in Platinum-Refractory Bladder Cancer

January 18th 2018

The PD-L1 inhibitor avelumab induced an overall response rate of 17% in patients with platinum-refractory metastatic urothelial carcinoma.

Molecular Subtypes Correlate With Outcomes in RCC

January 16th 2018

Molecular subtypes of clear-cell renal cell carcinoma were prognostic for outcomes after metastasectomy, with significant differences seen in overall survival and disease-free survival between groupings.

Dr. Voss Discusses Treatment in the Neoadjuvant Setting for Kidney Cancer

January 16th 2018

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses treatment in the neoadjuvant setting for patients with kidney cancer.

Dr. Plimack on Choosing a Checkpoint Inhibitor in Bladder Cancer

January 16th 2018

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses choosing a checkpoint inhibitor in bladder cancer.

Dr. Hammers on the Long-Term Benefits of the CheckMate-214 Study in RCC

January 11th 2018

Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the long-term benefits of the CheckMate-214 study in patients with renal cell carcinoma (RCC).

Combinations Continue to Advance RCC Treatment

January 11th 2018

Rana R. McKay, MD, discusses the evolving management of patients with advanced RCC, specifically the future of combinations of with immunotherapy regimens.

McDermott Shares Insight on Immunotherapy in RCC

January 10th 2018

David F. McDermott, MD, discusses the successes with immunotherapy in renal cell carcinoma and gave his insight on the future treatment of these patients.

Dr. Zhang on Toxicities of Treatments in RCC

January 9th 2018

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the tolerability of agents used for the treatment of patients with renal cell carcinoma (RCC).

Dr. Graff Discusses the Treatment of Prostate Cancer

January 9th 2018

Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses the treatment of prostate cancer.